CClinicalTrials.gg
Status unknownNCT03142347Updated May 5, 2017

Remote Endarterectomy vs Remote Endarterectomy + Drug Coated Balloon (DCB) Angioplasty in Patients With the Femoral Artery Occlusive Disease

An interventional study of Remote endarterectomy and Remote endarterectomy + DCB balloon in Femoral Artery Occlusion, sponsored by Meshalkin Research Institute of Pathology of Circulation. Status unknown at 1 site in Russian Federation. Open to participants aged 45 Years to 75 Years. Per ClinicalTrials.gov, last updated 2017-05-05.

Sponsored by Meshalkin Research Institute of Pathology of Circulation · Not applicable, Interventional, and Treatment

The sponsor has not verified this record recently (last verified May 2017), so the status shown — last known as Recruiting — may be out of date.

From the registry’s dates

  • Registered 4 months after the study started (first participant enrolled Jan 2017, registered May 2017).
Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
45 Years to 75 Years
Sex
All
01

Study summary

Comparison effectiveness two methods revascularization of the superficial femoral artery: remote endarterectomy vs. remote endarterectomy supplemented DCB angioplasty in patients with steno-occlusive lesion of the femoro-popliteal segment of TASCII D

Read the detailed description

Given that more and more devices appear to deliver cytotoxic drugs into the depth of atherosclerotic plaque, it is interesting to study the effect of these drugs when applied directly after plaque removal.

02

Conditions studied

  • Femoral Artery Occlusion

Keywords

  • remote endarterectomy
  • DCB balloon
03

In context

Lead sponsor

Meshalkin Research Institute of Pathology of Circulation is the lead sponsor of 114 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
45 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Patients with occlusive lesions of C and D type femoral artery and with chronic lower limb ischemia (II-IV degree by Fontaine, 4-6 degree by Rutherford)
  • Patients who consented to participate in this study.

Exclusion criteria

Exclusion Criteria:

  • Chronic heart failure of III-IV functional class by New York Heart Association (NYHA) classification.
  • Decompensated chronic "pulmonary" heart
  • Severe hepatic or renal failure (bilirubin> 35 mmol / l, glomerular filtration rate \<60 mL / min);
  • Polyvalent drug allergy
  • Cancer in the terminal stage with a life expectancy less than 6 months;
  • Acute ischemic
  • Expressed aortic calcification tolerant to remote endarterectomy
  • Patient refusal to participate or continue to participate in the study
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
50 participants (estimated)

Study arms

  • Active comparator
    Remote endarterectomy

    Open endarterectomy of the common, deep, initial of superficial femoral artery was performed. Delamination factory complex into the lumen of the loop. After that, the translational and rotational motions loops under fluoroscopic guidance, continuing detachment of plaque in the antegrade direction to the distal end of plaque. Plastic arteriotomy wounds performed patches of xenopericardium. Control patency of the arterial lumen is performed intraoperatively by X-ray angiography.

    Procedure: Remote endarterectomy

  • Experimental
    Remote endarterectomy + DCB balloon

    Open endarterectomy of the common, deep, initial of superficial femoral artery was performed. Delamination factory complex into the lumen of the loop. After that, the translational and rotational motions loops under fluoroscopic guidance, continuing detachment of plaque in the antegrade direction to the distal end of plaque. Plastic arteriotomy wounds performed patches of xenopericardium. And balloon angioplasty of superficial femoral artery with DCB balloon is perform. Control patency of the arterial lumen is performed intraoperatively by X-ray angiography.

    Procedure: Remote endarterectomy + DCB balloon

Interventions

  • ProcedureRemote endarterectomy

    Performed open endarterectomy of the common, deep, initial of superficial femoral artery. Proximal plaque exfoliate as far as possible in the superficial femoral artery. After that, the translational and rotational motions loops under fluoroscopic guidance, continuing detachment of plaque in the antegrade direction to the distal end of plaque. Plastic of arteriotomy wounds performed patches of xenopericardium. Control patency of the arterial vessel is performed intraoperatively by X-ray angiography. When rendering residual stenosis or intimal dissection, limiting blood flow, complemented by endovascular intervention plasticity.

  • ProcedureRemote endarterectomy + DCB balloon

    Performed open endarterectomy of the common, deep, initial of superficial femoral artery. Proximal plaque exfoliate as far as possible in the superficial femoral artery. After that, the translational and rotational motions loops under fluoroscopic guidance, continuing detachment of plaque in the antegrade direction to the distal end of plaque. Plastic of arteriotomy wounds performed patches of xenopericardium. And balloon angioplasty of superficial femoral artery with DCB balloon is perform. Control patency of the arterial vessel is performed intraoperatively by X-ray angiography. When rendering residual stenosis or intimal dissection, limiting blood flow, complemented by endovascular intervention plasticity.

06

What researchers measure

Primary outcomes

  1. the change of lumen in target vessel

    stenosis or occlusions

    Time frame: Baseline, 3 days after the operation, 6 month, 12 month, 2 years

Secondary outcomes

  1. Vessel wall thickness

    mm

    Time frame: 3 days after the operation, 6 month, 12 month, 2 years

  2. Number of participants with limb salvage

    Time frame: 3 days after the operation, 6 month, 12 month, 2 years

  3. Number of participants with complications in long-term period after the operation.

    Time frame: 3 days after the operation, 6 month, 12 month, 2 years

07

Study locations

1 of 1 sites recruiting
  • Federal State Institution Academician E.N.Meshalkin Novosibirsk State Research Institute Of Circulation Pathology Rusmedtechnology
    Novosibirsk, 630055, Russian Federation
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 5, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03142347
Lead sponsor
Meshalkin Research Institute of Pathology of Circulation
Responsible party
Sponsor
First posted
May 5, 2017
Start date
Jan 2017
Primary completion
Jan 2018 (estimated)
Completion
Jan 2019 (estimated)
Last update
May 5, 2017

Study contacts

Artem Rabtsun
Contact
a_rabtsun@meshalkin.ru
+79137078354
Andrey Karpenko
study director · cientific-Research Institute of Circulation Pathology named after Academician E. Meshalkin

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in May 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion